Stephen Barat

Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis

Mahmoud A. Ghannoum, L. Long, Emily L. Larkin et al. · Antimicrobial Agents and Chemotherapy · 2018 · 81 citations · Full text

Life Sciences, Microbiology, Pharmacology +17

The Toxicity of SCH 351591, a Novel Phosphodiesterase-4 Inhibitor, in Cynomolgus Monkeys

Patricia E. Losco, Ellen W. Evans, Stephen Barat et al. · Toxicologic Pathology · 2004 · 75 citations

Medicine, Pharmacology, Toxicology +16

A Novel 1,3-Beta- <scp>d</scp> -Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis

Emily L. Larkin, L. Long, N. Isham et al. · Antimicrobial Agents and Chemotherapy · 2019 · 49 citations · Full text

Medicine, Infectious Diseases, Pharmacology +14

Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β- <scp>d</scp> -Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

Vidmantas Petraitis, Rūta Petraitienė, Aspasia Katragkou et al. · Antimicrobial Agents and Chemotherapy · 2020 · 49 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an <i>In Vivo</i> Guinea Pig Cutaneous Infection Model

Mahmoud A. Ghannoum, N. Isham, D. Angulo et al. · Antimicrobial Agents and Chemotherapy · 2020 · 39 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17